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Abstract
Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/
day) in reducing cardiovascular events. Clinicians in Asia doubt tolerability of these doses for their patients. We therefore
analyzed data from this study and a parallel study TRANSCEND (Telmisartan Randomized Assessment Study in ACE
Intolerant Subjects with Cardiovascular Disease). Our objectives were to compare Asians and non-Asians with respect to the
following:
1) Effectiveness of telmisartan vs. ramipril in reducing cardiovascular events;
2) Proportions who reached the full dose of telmisartan, ramipril or placebo; and
3) Proportions of overall discontinuations, and discontinuations due to adverse effects.
Method: The ONTARGET study randomized 25,620 patients at risk of cardiovascular events to ramipril, telmisartan, or their
combination. The primary composite endpoint was death caused by cardiovascular disease, acute MI, stroke, and
hospitalization because of congestive heart failure. TRANSCEND randomized 5926 high-risk patients with a history of
intolerance to ACE-inhibitors to telmisartan or placebo. The primary outcome was the same. In this substudy, we compared
Asians and non-Asians as to how well they tolerated telmisartan (given in both studies) and ramipril (given in ONTARGET).
Results: 1) Telmisartan was non-inferior to ramipril in lowering the primary endpoint among Asians (RR=0.92; 95% CI: 0.74,
1.13); 2) more Asians achieved the full dose of either drug; 3) less withdrew (overall); and 4) less withdrew for adverse
effects. Furthermore, telmisartan was better tolerated than ramipril. This advantage was greater among Asians.
Conclusion and Significance: Although Asians had lower BMI than non-Asians, Asians tolerated both drugs better.
Regulatory agencies require reporting of safety and effectiveness data by ethnicity, but few comply with this requirement.
This study shows that safety data in ethnic subgroups can help assess applicability of results to specific populations.
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Introduction
Angiotensin-converting enzyme (ACE) inhibitors reduce car-
diovascular morbidity and mortality among patients at risk for
these events [1,2]. However, studies also show a high residual rate
of cardiovascular events despite treatment, and a significant
incidence of intolerance to these drugs. These problems have led
to interest in the role of Angiotensin Receptor Blockers (ARBs),
either as supplements to, or replacements for ACE inhibitors [3].
The ONTARGET and TRANSCEND studies are 2 of the
largest trials conducted to clarify the effect of ARBs on
cardiovascular morbidity and mortality among patients at risk.
In the ONTARGET study, 25,620 patients at risk of cardiovas-
cular events (but no heart failure) were randomized to receive the
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e13694ACE-inhibitor ramipril, the ARB telmisartan, or their combina-
tion. The primary composite endpoint was death caused by
cardiovascular disease, acute MI, stroke, or hospitalization because
of congestive heart failure. Results showed that telmisartan was
non-inferior to ramipril in reducing these cardiovascular events
among patients at risk [4]. Telmisartan was also better tolerated.
Combining the 2 drugs showed no added advantage.
In TRANSCEND, the effect of telmisartan was compared to
placebo, among 5926 patients at risk, who were intolerant to ACE-
inhibitors. The primary outcome was the same as in the
ONTARGET study. Results showed that the effect of telmisartan
on the primary outcome was of borderline significance, probably
because of an unexpectedly lower number of outcome events [5].
However, a pre-specified analysis combining these results with
another study on telmisartan, the PRoFESS trial [6] (Prevention
Regimen for Effectively Avoiding Second Strokes), showed a
significant reduction in events, especially with more prolonged
treatment.
Although these studies were conducted in 733 centers in 40
countries and regions, there is concern about the applicability of
trial results to specific populations [7]. Both ONTARGET and
TRANSCEND titrated telmisartan to a dose of 80 mg/day but
studies in Asia show that lower doses are prescribed at least 75% of
the time [8]. For ramipril, the target dose was 10 mg/day, but
lower doses are prescribed 85% of the time in the region [8]. It is
not surprising therefore, that in presentations of this study at
numerous meetings in Asia, the most common question was
whether Asians tolerated the drugs as well as non-Asians.
Many journals require race or ethnicity-specific data when
reporting outcomes of epidemiologic studies or clinic trials.
Because of space constraints however, this is rarely done [9].
The main goal of this paper, therefore, is to take a detailed look at
the tolerability and safety of telmisartan and ramipril, comparing
Asians and non-Asians in ONTARGET and TRANSCEND. Its
specific objectives are:
1) To compare Asians and non-Asians with respect to the
effectiveness of telmisartan vs. ramipril in reducing cardio-
vascular events in high risk patients;
2) To compare the proportions of Asians and non-Asians who
reached the full dose of telmisartan, ramipril or placebo in
both studies; and
3) To compare the proportions of overall discontinuations, and
discontinuations due to adverse effects, between Asians and
non-Asians in both studies.
In comparing Asians and Non-Asians, we decided to focus this
report on the tolerability of telmisartan vs. ramipril (ONTAR-
GET) and telmisartan vs. placebo (TRANSCEND). Tolerability of
the combination of ramipril and telmisartan will not be examined
because results of the ONTAGET study showed an increase in
adverse events in this arm.
Methods
The protocol was approved by regulatory authorities and the
ethics review committee at each participating institution. Informed
consent was obtained from every patient. Details of the
methodology of ONTARGET and TRANSCEND have been
previously reported [3]. Briefly, in ONTARGET, we enrolled
patients aged 55 or more, if they had coronary, peripheral, or
cerebrovascular disease or diabetes with end-organ damage
(n=25,620). Patients with the same characteristics but intolerant
to ACE inhibitors were randomly assigned to receive either
telmisartan or placebo in the TRANSCEND study (n=5926) [4].
Both studies were double-blind, with a median follow-up of 56
months.
Telmisartan was titrated to a full dose of 80 mg in both
ONTARGET and TRANSCEND. In the ONTARGET study,
ramipril was titrated to a full dose of 10 mg per day. The main
outcome was a composite of death from cardiovascular causes,
myocardial infarction, stroke, or hospitalization for heart failure.
The key secondary outcome was a composite of death from
cardiovascular causes, myocardial infarction, or stroke, which was
the primary outcome in the Heart Outcomes Prevention
Evaluation (HOPE) trial [1]. National coordinators and clinical
monitors supervised the recruitment and follow up of patients by
investigators at 733 centers in 40 countries and regions. All
outcomes were reviewed by a central adjudicating committee
whose members were unaware of study-group assignments. An
independent data and safety monitoring board reviewed all serious
adverse events.
Information on ethnicity was based on self-reports during
recruitment. For the purposes of this paper, Asian ethnicity
included the following:
1) South Asian (India, Sri Lanka, Pakistan, Bangladesh,
Afghanistan, Nepal),
2) Chinese (China, Hong Kong, Taiwan),
3) Japanese,
4) Malay, or
5) Other Asian (Korea, Papua New Guinea, Thailand,
Philippines, Indonesia, Vietnam, Cambodia, Laos, Myan-
mar/Burma, Bhutan).
Statistical Analysis
Analysis was done using SAS version 8.2 (SAS Institute, Cary,
NC). The primary analysis used a time-to-event approach and
included all Asian and non-Asian participants who were
randomized to ramipril and telmisartan arms in ONTARGET.
Treatment comparisons between telmisartan and ramipril using
the predefined non-inferiority margin 1.13, and between Asians
and non-Asians with regard to time-to-event related data (time to
occurrence of first event) were shown as hazard ratios with 95%
confidence intervals. A Cox regression model, with factors for
treatment, Asian ethnicity, and interactions, was used to examine
the treatment effect among Asian and non-Asian patients.
Treatment comparisons (telmisartan vs. ramipril in ONTARGET,
telmisartan vs. placebo in TRANSCEND) with regard to
tolerability were done using the x
2 test by comparing discontin-
uations and the proportion achieving the full dose. The Breslow-
Day method was used to test homogeneity among Asian and non-
Asian patients. All reported p-values (other than for non-
inferiority) were two sided. P,0.05 was considered significant.
Results
Overall, Asians accounted for 3521 out of 25,620 patients
randomized in ONTARGET, and 1261 out of 5926 patients
randomized in TRANSCEND. Table 1 compares key baseline
characteristics of Asians and Non-Asians in both studies. Risk
factors for atherosclerosis were about the same in terms of
prevalence of hypertension and smoking. Average age, blood
pressure, blood glucose, and lipid levels were likewise similar.
Asians tended to have lower BMI, a higher incidence of diabetes
and previous stroke, slightly less coronary disease, more angio-
plasties, and less bypass surgeries. Statins and diuretics were used
ONTARGET Asian Substudy
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among Asians.
Cardiovascular Events
Table 2 shows the incidence of cardiovascular events on
ramipril and telmisartan. In the overall study result, telmisartan
was proven non-inferior to ramipril (HR=1.01; 95% CI: 0.94–
1.09). In this report, we show that this was a consistent result in the
subgroup of Asians (HR=0.92; 95% CI:0.74–1.13) as well as non-
Asians (HR=1.03; 95% CI:0.95–1.11). As can be seen in Table 2,
there was no difference between these 2 groups in terms of hazard
ratio for the primary composite outcome.
Absolute rates of the composite outcome were generally the
same, with slightly less events among Asians on telmisartan
(HR=0.87; 95% CI:0.74,1.02), but this did not reach statistical
significance (p=0.082). A more detailed comparison of the
individual rates of cardiovascular death, MI, stroke or admission
for CHF was also performed. This showed that overall, in the
ONTARGET study, strokes were more common among Asians
(5.9% vs. 4.3%, HR=1.4; 95% CI:1.17–1.69; p=0.003), while
MI was more common among non-Asians (5.2% vs. 3.8%;
HR=1.35; 95% CI:1.09,1.67; p=0.008). These differences
persisted even after adjustment for differences in baseline
characteristics (p=0.042 for the difference in stroke, and
p=0.014 for the difference in the incidence of MI).
Proportion Achieving Full Dose
Overall, a slightly lower proportion of patients achieved full
dose ramipril (10 mg) than telmisartan (80 mg) in the ONTAR-
GET study (74.8% vs. 79.8% respectively, p,0.0001). In both
ONTARGET and TRANSCEND significantly more Asians than
non-Asians achieved the target doses of ramipril and telmisartan
(Table 3).
Table 1. Baseline Characteristics of Asians and Non-Asians in the ONTARGET and TRANSCEND studies.
ONTARGET TRANSCEND
ASIANS NON-ASIANS ASIANS NON-ASIANS
(n=3521) (n=22,092*) (n=1261) (n=4665)
Mean age (years) 65.48 66.58 65.64 67.2
Male Sex (%) 73.7 73.3 59.7 56.3
Hypertension (%) 69.1 68.7 73.4 77.2
Diabetes (%) 43.1 36.6 41.7 34.1
Stroke or TIA (%) 30.3 19.3 34.2 18.7
Coronary disease (%) 71.1 75.1 70.1 75.8
Current Smokers (%) 12.3 12.6 10.6 9.6
Mean Systolic BP (mmHg) 141 142 140 141
Mean BMI (KG/m
2) 25.5 28.51 25.9 28.73
Mean cholesterol (mmol/Li) 4.97 4.94 4.99 5.11
Mean HDL (mmol/Li) 1.25 1.26 1.27 1.28
Mean LDL (mmol/Li) 2.95 2.92 2.98 3.04
Mean triglycerides (mmol/Li) 1.73 1.73 1.77 1.78
Fasting glucose (mmol/Li) 6.73 6.67 6.55 6.49
Prior coronary bypass (%) 11.0 23.9 10.3 21.2
Prior PTCA (%) 35.1 28.1 32.4 24.5
Statin use (%) 49.5 63.5 48.4 57.1
Beta-Blocker use (%) 52.2 57.7 52.0 60.0
Aspirin use (%) 77.6 75.4 73.5 75.0
Thienopyridine use (%) 9.1 11.3 10.7 10.7
Diuretic use (%) 18.1 29.5 22.5 35.8
Calcium blocker use (%) 43.9 31.3 50.0 37.5
*7 patients with missing ethnicity.
BP=blood pressure; BMI=body mass index; HDL=high density lipoprotein cholesterol; LDL=low density lipoprotein cholesterol; PTCA=percutaneous transluminal
coronary angioplasty.
doi:10.1371/journal.pone.0013694.t001
Table 2. Risk of the primary outcome (cardiovascular death,
MI, stroke or admission for CHF) on Ramipril and Telmisartan,
comparing Asians and Non-Asians in the ONTARGET Study.
Overall Asian Non-Asian p-value
{
Ramipril 1412 (16.46%) 190 (16.07%) 1221 (16.52%) 0.775
Telmisartan 1423 (16.66%) 171 (14.59%) 1252 (16.99%) 0.082
HR (95% CI)
* 1.01 (0.94–1.09) 0.92 (0.74–1.13) 1.03 (0.95–1.11) 0.305
1
p-value
" 0.004 0.046 0.020 -
*Risk in telmisartan/ramipril group.
"p-value (telmisartan vs. ramipril) based on non-inferiority margin 1.13.
{p-value (asians vs. non-asians).
1p for interaction.
doi:10.1371/journal.pone.0013694.t002
ONTARGET Asian Substudy
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placebo in the TRANSCEND study, suggesting that Asians, were
simply more compliant than non-Asians. However, this does not
explain why, in ONTARGET, the difference favoring telmisartan
over ramipril was significantly greater among Asians than non-
Asians (p=0.0003).
Withdrawals
Table 4 shows that overall, in the ONTARGET study, there were
more discontinuations in the ramipril group than in the telmisartan
group (RR=0.95; 95% CI: 0.90,1.00). There was no indication that
Asians could not tolerate the doses at which either drug was given.
On the contrary, there were significantly more discontinuations
among non-Asians on either ramipril or telmisartan.
In the TRANSCEND study, the lower rates of discontinuation
among Asians on placebo suggests that Asians were simply more
tolerant than non-Asians. However ONTARGET shows that the
reduction in discontinuations with telmisartan compared to
ramipril was more marked in Asians than in non-Asians
(p=0.003). This is consistent with the results on proportions of
patients achieving full dose.
Table 5 tells a similar story, looking at permanent discontin-
uations that were specifically caused by side effects. There was no
significant difference between Asians and non-Asians with respect
to side effects from ramipril (p=0.74). However, Asians tolerated
telmisartan better than non-Asians (p=0.0001 for ONTARGET,
and p,0.0001 for TRANSCEND).
We also looked at differences in rates of discontinuation for
specific reasons. Except for the higher incidence of cough among
Asians (table 6) and the lower incidence of hypotension, we found
no difference between Asians and non-Asians. Overall, in
ONTARGET, the relative benefit from use of telmisartan showed
a reduction in discontinuations because of cough (RR=0.26; 95%
CI: 0.21, 0.33). This was about the same in Asians and non-Asians,
but the absolute risk of cough was higher in Asians. In the
Ramipril group, 6.1% of Asians stopped because of cough,
Table 3. Percent of Patients Achieving Full Dose Ramipril,
Telmisartan or placebo at the end of the ONTARGET and
TRANSCEND studies.
Overall Asians Non-Asians p-value
{
ONTARGET
Ramipril 5730 (74.82%) 826 (77.92%) 4903 (74.32%) 0.012
Telmisartan 6103 (79.82%) 922 (87.56%) 5180 (78.60%) 0.0001
RR (95% CI)
* 1.08(1.05,1.09) 1.12(1.08,1.17) 1.06(1.04,1.08) 0.0003
1
p-value
" ,0.0001 ,0.0001 ,0.0001 -
TRANSCEND
Placebo 2088 (79.09%) 501 (86.68%) 1587 (76.96%) ,0.0001
Telmisartan 2086 (79.44%) 500 (86.36%) 1586 (77.48%) ,0.0001
RR (95% CI)
** 1.00(0.98,1.03) 1.00(0.95,1.04) 1.01(0.97,1.04) 0.762
1
p-value
d 0.757 0.872 0.694 -
*Risk in telmisartan/ramipril group.
"p-value (telmisartan vs. ramipril).
**Risk in telmisartan/placebo group.
dp-value (telmisartan vs. placebo).
{p-value (asians vs. non-asians).
1p for interaction.
doi:10.1371/journal.pone.0013694.t003
Table 4. Overall Discontinuations in Percent, in ONTARGET
and TRANSCEND.
Overall Asians Non-Asians p-value
{
ONTARGET Study
Ramipril 2121 (24.73%) 235 (19.88%) 1885 (25.50%) ,0.0001
Telmisartan 2000 (23.41%) 169 (14.42%) 1829 (24.83%) ,0.0001
RR (95% CI)
* 0.95 (0.90,1.00) 0.73 (0.61,0.87) 0.97 (0.92,1.03) 0.003
1
p-value
" 0.044 0.0004 0.346 -
TRANSCEND Study
Placebo 705 (23.72%) 82 (13.14%) 623 (26.53%) ,0.0001
Telmisartan 639 (21.63%) 83 (13.03%) 556 (24.00%) ,0.0001
RR (95% CI)
** 0.91 (0.83,1.00) 0.99(0.75,1.32) 0.9(0.82,1.00) 0.489
1
p-value
d 0.055 0.953 0.046 -
*Risk in telmisartan/ramipril group.
"p-value (telmisartan vs. ramipril).
**Risk in telmisartan/placebo group.
dp-value (telmisartan vs. placebo).
{p-value (asians vs. non-asians).
1p for interaction.
doi:10.1371/journal.pone.0013694.t004
Table 5. Percent Permanent Discontinuations Because of
Side effects in ONTARGET and TRANSCEND.
Overall Asians Non-Asians p-value
{
ONTARGET Study
Ramipril 1005(11.72%) 135(11.42%) 869 (11.76%) 0.740
Telmisartan 835(9.78%) 77 (6.57%) 757 (10.28%) 0.0001
RR (95% CI)
* 0.83(0.76,0.91) 0.58(0.44,0.75) 0.87 (0.80,0.96) 0.004
1
p-value
" ,0.0001 ,0.0001 0.004 -
TRANSCEND Study
Placebo 163 (5.49%) 18 (2.89%) 145 (6.18%) 0.001
Telmisartan 214 (7.24%) 22(3.45%) 192 (8.29%) ,0.0001
RR (95% CI)
** 1.32 (1.08,1.61) 1.2(0.65,2.21) 1.34(1.09,1.65) 0.702
1
p-value
d 0.006 0.564 0.005 -
*Risk in telmisartan/ramipril group.
"p-value (telmisartan vs. ramipril).
**Risk in telmisartan/placebo group.
dp-value (telmisartan vs. placebo).
{p-value (asians vs. non-asians).
1p for interaction.
doi:10.1371/journal.pone.0013694.t005
Table 6. Percent Discontinuations Because of Cough in the
ONTARGET Study.
Overall Asians Non-Asians p-value
{
Ramipril 360 (4.2%) 72 (6.1%) 288(3.9%) ,0.001
Telmisartan 93(1.1%) 17(1.45%) 76 (1.03%) 0.200
RR (95% CI)
* 0.26 (0.21,0.33) 0.24 (0.14,0.4) 0.26 (0.21,0.34) 0.679
1
p-value
d ,0.0001 ,0.0001 ,0.0001
*Risk in telmisartan/ramipril group.
dp-value (telmisartan vs. ramipril).
{p-value (asians vs. non-asians).
1p for interaction.
doi:10.1371/journal.pone.0013694.t006
ONTARGET Asian Substudy
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discontinuation due to hypotension in Asians was lower than in
non-Asians (1.3% vs. 3.3%, p,0.0001 in ONTARGET and 0.2%
vs. 0.9%, p=0.016 in TRANSCEND). Despite these differences,
there were more overall discontinuations among non-Asians.
There were no significant differences in the other specific reasons
for discontinuation such as syncope or angioedema.
Discussion
Telmisartan was non-inferior to ramipril in lowering the risk of
cardiovascular death, stroke, MI or admission for CHF, and was
slightly better tolerated. This was a consistent finding among
Asians and non-Asians in the ONTARGET study. The similarity
in absolute event rates between Asians and non-Asians reassures us
that there were no adverse differences related to the primary
outcomes.
Our measures of tolerability included the proportion of patients who
achieved the full dose at the study’s end, and the proportion who had to
discontinue permanently. Both measures showed an interesting trend,
that Asians were generally more tolerant, even when they were on
placebo. Possible explanations include the following:
1) Asians are more tolerant and compliant to their prescribed
medications in general;
2) Most principal investigators in the participating centers from
the Asian countries and regions were also the responsible
physician for their patients. This may have provided
supportive reassurance when minor side effects develop.
These differences do not affect the validity of the noted
differences between telmisartan and ramipril in ONTARGET,
and between telmisartan and placebo in TRANSCEND, because
both trials were double blind, and the proportion of Asians was
equal in all treatment groups. Furthermore, while these differences
may explain the higher tolerance of Asians for both ramipril and
telmisartan, they do not explain why the advantage of telmisartan
over ramipril was greater among Asians than non-Asians (tables 3
and 4). This observation raises the possibility that there may be
ethnic differences in the relative tolerance to these 2 classes of
drugs in RAA inhibition. Ethnic differences in drug tolerability are
well documented, especially in the case of cardiovascular drugs
[10]. These differences may be related to cultural factors such as
diet [11] or compliance, or genetic factors such as drug
metabolism or RAA activity [12–14].
Our findings are consistent with previous literature showing that
cough is more common among Asians [15]. Asian ethnicity, in
fact, has become a component of clinical prediction rules that
estimate risk for cough for patients given ACE-inhibitors [16].
Nevertheless, in this study, overall compliance and tolerance of
both drugs was better among Asians, and better with telmisartan
compared to ramipril. These findings should allay fears that Asians
may have lower tolerance for the doses of ramipril and telmisartan
that were used in these studies to lower cardiovascular risk. Thus,
it would be appropriate to use the same dose of these medications
in both Asians and non-Asians.
Although Asians were indeed smaller in body size than non-
Asians in both studies, there was no evidence that any of the drugs
were tolerated less. Regulatory agencies require trials to present a
summary of safety and effectiveness data by ethnicity but few
publications comply with this requirement for reporting [17].
Large International studies like ONTARGET and TRANSCEND
offer the advantage of wide representation from various ethnic
groups, which can aid us in evaluating local applicability of the
results. Publication of results in ethnic subgroups from these trials
can help allay concerns regarding applicability.
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